Report Overview
Radionuclide Drug Conjugate(RDC) are a form of drug designed and developed by coupling precise targeting molecules (monoclonal antibodies or peptides/small molecules, ligands) and powerful killing factors (nuclide, radioisotopes) together with linkers. The global Radionuclide Drug Conjugate(RDC) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030. Analytic Insights Hub's' newest research report, the ?Radionuclide Drug Conjugate(RDC) Industry Forecast? looks at past sales and reviews total world Radionuclide Drug Conjugate(RDC) sales in 2022, providing a comprehensive analysis by region and market sector of projected Radionuclide Drug Conjugate(RDC) sales for 2023 through 2029. With Radionuclide Drug Conjugate(RDC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radionuclide Drug Conjugate(RDC) industry. This Insight Report provides a comprehensive analysis of the global Radionuclide Drug Conjugate(RDC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radionuclide Drug Conjugate(RDC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Radionuclide Drug Conjugate(RDC) market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radionuclide Drug Conjugate(RDC) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radionuclide Drug Conjugate(RDC). United States market for Radionuclide Drug Conjugate(RDC) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. China market for Radionuclide Drug Conjugate(RDC) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. Europe market for Radionuclide Drug Conjugate(RDC) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. Global key Radionuclide Drug Conjugate(RDC) players cover Novartis, Telix Pharmaceuticals, Lantheus, Curium, Yuanda Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023. This report presents a comprehensive overview, market shares, and growth opportunities of Radionuclide Drug Conjugate(RDC) market by product type, application, key players and key regions and countries. Segmentation by Type: Therapy Diagnosis Segmentation by Application: Prostate Cancer Neuroendocrine Cancer Other This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries Segmentation by Type: Therapy Diagnosis Segmentation by Application: Prostate Cancer Neuroendocrine Cancer Other This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Novartis Telix Pharmaceuticals Lantheus Curium Yuanda Pharmaceuticals China Tongfang Pharmaceuticals Dongcheng Pharmaceuticals Kelun Biotech Hengrui Bayer Zhihe Biotechnology Fulian Pharmaceuticals